Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lentiviral Gene Transfer for X-Linked SCID
NCT03315078Phase 2Unknown
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2012
- Primary completion
- Dec 2022
- Modality
- Gene Editing, Gene Silencing, Hematopoietic Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of MB-117 in X-linked severe combined immunodeficiency (X-SCID), sponsored by National Institute of Allergy and Infectious Diseases. Status: unknown.
02
Drugs
MB-117
03
Conditions
X-linked severe combined immunodeficiency (X-SCID)
Beyond the preview
Go deeper on NCT03315078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315078.